Get the Stockscreener App
3.41
2.57%
-0.09
After Hours:
3.42
0.010
+0.29%
Rocket Pharmaceuticals Inc stock is traded at $3.41, with a volume of 954.00K.
It is down -2.57% in the last 24 hours and down -12.79% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.50
Open:
$3.49
24h Volume:
954.00K
Relative Volume:
0.41
Market Cap:
$374.33M
Revenue:
-
Net Income/Loss:
$-209.38M
P/E Ratio:
-1.8169
EPS:
-1.8768
Net Cash Flow:
$-179.81M
1W Performance:
-2.57%
1M Performance:
-12.79%
6M Performance:
+4.92%
1Y Performance:
+17.18%
1-Day Range:
$3.40
$3.55
1-Week Range:
$3.37
$3.7099
52-Week Range:
$2.53
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.41 | 384.21M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5 - moomoo.com
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus - Zacks Investment Research
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside - TradingView
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15 - GuruFocus
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a shareEarnings Preview - TradingView
ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12 - Bitget
ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings - Quiver Quantitative
Rocket Pharmaceuticals: Q2 Earnings Snapshot - KTVB
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
Rocket Pharmaceuticals Q2 Results: Net income turns positive on PRV sale - scanx.trade
BRIEF-Rocket Pharmaceuticals Q2 EPS USD 1.08 - Bitget
Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 6c; offers guidance - StreetInsider
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale - TradingView
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - Business Wire
Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
How (RCKT) Movements Inform Risk Allocation Models - Stock Traders Daily
Rocket Pharmaceuticals, Inc. Revenue Breakdown – BOATS:RCKTW - TradingView
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com Nigeria
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - moomoo.com
Rocket Pharmaceuticals reports positive safety update for RP-A501 in Phase 2 Danon trial - TradingView
Rocket Pharma reports early safety data for Danon disease therapy By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.com
Rocket Pharma reports early safety data for Danon disease therapy - Investing.com
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a 192% Potential Upside in Genetic Therapy Innovations - DirectorsTalk Interviews
Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Thursday - MarketBeat
Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation? (NASDAQ:RCKT) - Seeking Alpha
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RCKT|Rocket Pharmaceuticals Inc|Price:3.240|Chg%:+0.050 - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
If You Invested $1,000 in Rocket Pharmaceu (RCKT) - Stock Titan
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - The National Law Review
Rocket Pharmaceuticals, Inc. Revenue Breakdown – MUN:9IP1 - TradingView
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a Potential 186% Upside in Genetic Therapy Innovation - DirectorsTalk Interviews
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Frontier tech research, news & data - MLQ.ai
Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends - Ad-hoc-news.de
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks - TradingView
Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1 - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake - Stock Titan
Price to earnings forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - AOL.com
Form 144 ROCKET PHARMACEUTICALS For: 7 July By Investing.com - Investing.com South Africa
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.12%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):